Thursday, March 04, 2021 11:38:23 PM
Ratna1, maybe you are referring to this...
Most people with an IgA deficiency don’t have any symptoms of the health problem. It’s usually found on a blood test, if it’s found at all. About 1 in 4 to 1 in 2people with selective IgA deficiency will be affected. Some people with an IgA deficiency are more likely to get frequent infections. These can include sinus, lung, and digestive infections. Some people with IgA deficiency also are more likely to have allergies, and digestive and autoimmune problems such as celiac disease or lupus.
https://www.hopkinsmedicine.org/health/conditions-and-diseases/immunoglobulin-a-deficiency
The addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced. Both these effects were restricted to LPMC. LDA showed that the IgA-enhancing effect was associated with an increase in the number of IgA-producing precursor cells and with variation in the regulatory phenomena involved in IgA production.
https://pubmed.ncbi.nlm.nih.gov/8119526/
Most people with an IgA deficiency don’t have any symptoms of the health problem. It’s usually found on a blood test, if it’s found at all. About 1 in 4 to 1 in 2people with selective IgA deficiency will be affected. Some people with an IgA deficiency are more likely to get frequent infections. These can include sinus, lung, and digestive infections. Some people with IgA deficiency also are more likely to have allergies, and digestive and autoimmune problems such as celiac disease or lupus.
https://www.hopkinsmedicine.org/health/conditions-and-diseases/immunoglobulin-a-deficiency
The addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced. Both these effects were restricted to LPMC. LDA showed that the IgA-enhancing effect was associated with an increase in the number of IgA-producing precursor cells and with variation in the regulatory phenomena involved in IgA production.
https://pubmed.ncbi.nlm.nih.gov/8119526/
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
